BioAge Labs (BIOA) Operating Leases (2025 - 2026)
BioAge Labs' (BIOA) quarterly Operating Leases came in at $2.1 million in Q2 2026, down 15.83% year-over-year from $2.5 million in Q2 2025, and down 4.85% quarter-over-quarter from $2.2 million in Q1 2026.
Powered by 
Analysis
BioAge Labs (BIOA) Operating Leases (2025 - 2026) Analysis & Trends
BioAge Labs has disclosed Operating Leases across 2 years of filings, most recently posting $2.1 million for Q2 2026.
- In Q2 2026, Operating Leases fell 15.83% year-over-year to $2.1 million; the TTM figure through Jun 2026 stood at $2.1 million (down 15.83% YoY), while the FY2025 annual figure was $2.3 million, changed N/A from the prior year.
- Operating Leases came in at $2.1 million for Q2 2026 at BioAge Labs, down from $2.2 million in the prior quarter.
- In the past five years, Operating Leases ranged from a high of $2.6 million in Q1 2025 to a low of $2.1 million in Q2 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 207.59 Bn | 193.60 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 178.73 Bn | 175.55 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 131.17 Bn | 123.32 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 81.73 Bn | 73.73 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.01 Bn | 55.82 Bn | 1.37 Bn |
| 6 | Moderna | 53.40 Bn | 48.27 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.49 Bn | 30.18 Bn | 992.69 Mn |
| 8 | Biogen | 31.64 Bn | 30.35 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.66 Bn | 29.66 Bn | 1.16 Mn |
| 10 | BioAge Labs | 398.39 Mn | 398.39 Mn | -14.23 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 2.12 Mn |
| Mar 31, 2026 | 2.23 Mn |
| Dec 31, 2025 | 2.33 Mn |
| Sep 30, 2025 | 2.43 Mn |
| Jun 30, 2025 | 2.52 Mn |
| Mar 31, 2025 | 2.56 Mn |